CTIS.eu › Cities › France › Paris
Paris
France
2,286 total trials
1,022 recruiting
Filter these 2,286 trials by phase, condition, sponsor and more.
Open in Search →
2023-504487-41-00
5
2023-11-28
COVID-19
2023-503418-63-00
4
2023-11-23
Head and Neck Squamous Cell Carcinoma
2023-504545-31-00
1
2023-11-23
colorectal cancer
2022-501418-69-00
5
2023-11-21
Acute Coronary Syndrome
2022-502068-19-00
5
2023-11-16
Moderate to severe rotator cuff tendinopathy
2022-502881-25-00
4
2023-11-16
Hemophilia B
2022-502339-20-00
4
2023-11-15
Squamous cell carcinoma of head and neck
2022-502880-39-00
4
2023-11-13
Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
2022-500777-14-00
4
2023-11-06
Atopic Dermatitis
2022-502227-22-00
4
2023-10-25
Autoimmune disease
2022-502476-23-00
4
2023-10-25
Treatment of immunotherapy-naive patients with previously untreated or
2023-504418-30-00
4
2023-10-24
Idiopathic Pulmonary Fibrosis
2022-502372-22-01
4
2023-10-19
Metastatic Breast Cancer HR+, HER2-
2022-501074-19-00
10
2023-10-13
Hidradenitis suppurativa
2022-502360-21-00
4
2023-10-12
GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast
2022-500568-37-00
5
2023-10-11
Masseter Muscle Prominence
2022-502148-10-00
5
2023-10-10
Paroxysmal Nocturnal Hemoglobinuria (PNH)
2022-500883-37-00
7
2023-10-02
This FTiH-PoC study aims to provide an early evaluation of the efficac
2022-503067-15-00
5
2023-10-02
Tuberous Sclerosis Complex (TSC) related epilepsy
2023-503576-25-00
5
2023-09-22
Severe Hypertriglyceridemia
2022-500930-27-00
3
2023-09-15
Solid Tumor
2022-501895-25-00
5
2023-09-13
Polymyalgia Rheumatica
2022-502174-16-00
5
2023-09-13
Macular edema secondary to retinal vein occlusion
2024-515489-15-00
5
2023-09-06
Activated Phosphoinositide 3-Kinase Delta Syndrome
Showing 1,945–1,968 of 2,286 trials